- Price then
- INR 266
- Market cap then
- INR 929 Cr.
Wanbury Ltd is an integrated pharmaceutical company focused on APIs, with a complementary branded formulations business. Minerva Capital Research Solutions gives the stock a Positive outlook; it does not state a target price or a Buy, Hold or Sell rating. The investment case centres on a financial turnaround, improving margins and planned API launches, balanced against product concentration, debt repayments and execution risks.
About Wanbury
Incorporated in 1988, Wanbury is an integrated pharmaceutical company primarily focused on active pharmaceutical ingredients (APIs), alongside branded formulations. It operates two USFDA-approved manufacturing facilities at Tanuku, Andhra Pradesh and Patalganga, Maharashtra, with cumulative installed reactor capacity of 500 KL. Its formulations business is primarily domestic, while around 80% of API sales are exported to more than 50 countries. FY25 sales were INR 600 Cr., with APIs contributing 88% and formulations 12%.
Why We Recommend Wanbury
The report gives Wanbury a Positive outlook but does not state a formal Buy, Hold or Sell recommendation.
- Established API positions: Wanbury has estimated company market shares of ~11% in Metformin, ~30% in Sertraline and ~11% in Tramadol. Metformin and Sertraline made up 50% and 40% of FY25 API sales mix, respectively.
- Debt refinancing and turnaround: In Mar’25, the company refinanced debt from 21% NCDs to 12.5% for up to INR 175 Cr. Infomerics subsequently upgraded its rating to IVR BBB-/Stable from IVR C+/Negative/Issuer Not Cooperating.
- New API launches: After commercializing an anaesthetic in Q4FY26, the company plans four new additions each year from FY27. Planned molecules include Dextromethorphan HBr, Ketamine HCl, Rivaroxaban and Sitagliptin.
- Margin improvement: Process benchmarking with E&Y has supported raw-material cost optimization through improved input-output ratios and higher batch yields. Wanbury targets API gross margins of 50%+.
- Capacity and cash generation: Tanuku has potential for brownfield expansion, with the company targeting reactor capacity of 600KL from the existing 500KL. The report notes CFO remained positive from FY19 to FY25.
Wanbury Key Financials
| Particulars | FY24 | FY25 | H1-FY26 | 9M-FY26 |
|---|---|---|---|---|
| Op. Revenues | 578 | 600 | 323 | 486 |
| Growth Y-o-Y % | 15.6% | 3.8% | 10.6% | 13.6% |
| EBITDA | 72 | 76 | 50 | 77 |
| EBITDA % | 12.5% | 12.7% | 15.5% | 15.8% |
| PAT | 56.0 | 30.5 | 28.7 | 44.4 |
| PAT % | 9.7% | 5.1% | 8.9% | 9.1% |
| Total Debt | 116 | 177 | 196 | |
| Equity | 28 | 59 | 107 | |
| Debt / Equity | 4.14x | 2.98x | 1.83x |
Operating revenue rose to INR 600 Cr. in FY25 from INR 578 Cr. in FY24. In 9M-FY26, revenue was INR 486 Cr. and EBITDA margin was 15.8%.
Valuation and Target Price
Wanbury trades at a PE(x) of 15.7x annualized 9MFY26 PAT. The report describes the stock as a “Growth at Value” pick and says sales growth alongside sustainable margins could support potential upward re-rating. Q4FY26 results and management commentary are key monitorables. The report states a Positive outlook but provides no target price, upside or formal Buy, Hold or Sell rating.
- INR 266
- CMP
- INR 929 Cr.
- Market capitalization
- Positive
- Outlook
Key Risks
- Product concentration and commoditization: APIs contribute ~88% of total sales, while Metformin and Sertraline account for ~90% of API revenues. Metformin faces intense competition and limited pricing power; Sertraline has better entry barriers.
- Debt and repayment obligations: As on Sep’25, debt of INR 196 Cr. against equity of INR 107 Cr. translated into Debt to Equity of 1.83x and Debt to EBITDA of 1.95x. Quarterly repayments of Investec NCDs were scheduled to start from 20-Feb’26.
- Launch and capex execution: The plan to launch four products every year from FY27 is exposed to regulatory risks, approval timelines and the challenge of reaching commercial scale.
Business and Growth Plans
- API portfolio: The existing portfolio comprises six molecules. Metformin and Sertraline are the largest contributors to API sales; the report characterizes Metformin as a high-volume, low-price commodity-like API and notes regulatory complexity as a moat for Sertraline.
- Pipeline and revenue potential: The planned API launches are being developed in-house. The company expects them to contribute INR 60-70 Cr. in incremental revenues, translating into 7-9% of growth p.a.; it targets gross margins of 50%.
- Capital expenditure: Planned capex is INR 64 Cr. in FY26 and INR 63 Cr. in FY27, to be funded primarily through internal accruals and existing NCDs.
- Formulations: The branded formulations portfolio covers several therapeutic areas and supplements. The business uses fully outsourced manufacturing and emphasizes brand building; the network includes 300+ field force, 1,800+ distributors and 30,000+ doctors engaged.
Management
The report describes Wanbury as having an operating track record of over 37 years in the pharmaceutical industry, led by an experienced promoter group involved in the company’s strategic direction and turnaround.
Our View
The report’s positive view rests on the financial turnaround, recent margin expansion, established positions in select APIs and a planned launch pipeline. High product concentration, debt repayments and the execution required for launches and capex remain important risks. Q4FY26 results and management commentary are identified as key monitorables.
Standard disclosures
- Research Analyst has served as an officer, director or employee of subject company(ies): No
- We or our associates have received compensation from the subject company(ies) in the past 12 months: No
- We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past12 months: No
- We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months –No
- We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report –No
- We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies)- No
- Nature of financial interest in subject company, if any –Nil
- We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of Research Report – No
- Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report-No.
- We or our Associates or Research Analyst are engaged in market making of subject company – No
- By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
- There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.
Regulatory disclosures
Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta(SEBI registration no. INH000018896).
Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.
The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness.
The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report may or may not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions.
Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report.
This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.
For any queries or grievances: Mr. Nishant Gupta | Email: nishant.gupta@mcapital.in or guptanishant.iimi@gmail.com| Contact Number: 8171433387 | Website: www.mcapital.in | Twitter: @Mcapital_In
Rating rationale
Minerva Capital Research Solutions endeavors to provide objective opinions and recommendations. Ratings are assigned to stocks according to their fair value vs current market price and then categorizes them as Buy, Hold, Reduce, Sell. The performance horizon is one year unless specified and fair value is defined as analyst’s valuation for a stock.
- Buy:> 15%
- Hold: -5% to 15%
- Reduce: -15% to -5%
- Sell: <-15%